Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Andry

Sleep Medicine San Antonio, TX Medical Doctor

NPI 1316010986 CMS profile 13563

5290 Medical Dr, San Antonio, TX 78229

Open in the dashboard

General payments

$99,779

224 records reported · program years 2019–2025

Research payments

$118,754

Paid to them · 35 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,953,826 paid to institutions, not to them · program years 2019–2025

Through program year 2025, James Andry of San Antonio, TX is reported in the CMS Open Payments database as having received $99,779 across 224 general payments and $118,754 in research payments paid to them. Separately, studies naming them as principal investigator received $1,953,826 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,218 56
2024 General $6,275 44
2023 General $3,734 11
2023 Research $1,059 1
2022 General $6,101 10
2022 Research $114,288 4
2021 General $13,872 22
2020 General $2,923 9
2020 Research $2,477 28
2019 General $50,655 72
2019 Research $930 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Andry
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to James Andry were reported at $16,218. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year James Andry Sleep Medicine median Middle half National median
2019 $50,655 $185 $66–$736 $163
2020 $2,923 $149 $46–$504 $114
2021 $13,872 $191 $62–$750 $132
2022 $6,101 $246 $92–$972 $149
2023 $3,734 $321 $119–$1,033 $160
2024 $6,275 $393 $111–$1,207 $164
2025 $16,218 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $60,573 97 payments
  2. Harmony Biosciences LLC $16,899 33 payments
  3. Eli Lilly and Company $12,991 21 payments
  4. Lilly USA, LLC $4,656 10 payments
  5. Amgen Inc. $1,674 3 payments
  6. Eisai Inc. $886 9 payments
  7. Inspire Medical Systems, Inc. $875 31 payments
  8. Axsome Therapeutics, Inc. $401 6 payments
  9. Avadel Specialty Pharmaceuticals, LLC $225 2 payments
  10. Respicardia, Inc. $169 3 payments
  11. Other $428 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,859 26 payments
  2. Food and Beverage $16,133 127 payments
  3. Travel and Lodging $12,549 58 payments
  4. Consulting Fee $11,153 11 payments
  5. Education $85 2 payments
Products named General payments · program years 2019–2025
  1. SUNOSI Pain $50,163 64 payments
  2. Wakix Neurological Disorders $13,162 23 payments
  3. SUNOSI Neurology $9,251 12 payments
  4. MOUNJARO $3,768 3 payments
  5. WAKIX Sleep Medicine $3,630 6 payments
  6. INSPIRE $875 31 payments
  7. XYREM $496 8 payments
  8. XYWAV $474 13 payments
  9. Sunosi Neurology $401 6 payments
  10. Noctiva $225 2 payments
  11. Other $990 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $115,347 5 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $3,407 30 payments

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$226,934

Medicare's payments for the services billed

Medicare patients

657

Average age 71

Services billed

2,716

309 women, 348 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 38%
Ischemic heart disease 33%
Depression 27%
Chronic kidney disease 24%
Atrial fibrillation 17%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $3,750
$3,750 — —
Sunosi
  • Axsome Therapeutics, Inc. $401
$401 — —
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $132
$132 — —
XYREM
  • JAZZ PHARMACEUTICALS INC. $91
$91 — —
WAKIX
  • Harmony Biosciences LLC $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record